Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer

X Xueping Qu H Habib Hamidi R Radia M. Johnson E Ethan S. Sokol E Eva Lin (Merck Center for Catalysis at Princeton University) C Cathy Eng (Vanderbilt-Ingram Cancer Center, Nashville) T Tae Won Kim (Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea) J Johanna Bendell S Smruthy Sivakumar B Benjamin Kaplan F Felipe De Sousa E Melo A Andrew Mancini M Matthew Wongchenko Y Yi Shi (School of Materials Science and Engineering, Key Laboratory for Polymeric Composite and Functional Materials of Ministry of Education, Guangdong Functional Biomaterials Engineering Technology Research Center) D David Shames Y Yibing Yan F Fortunato Ciardiello C Carlos Bais